You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The assay from San Diego-based Cue is the first molecular test authorized by the US Food and Drug Administration for home use without a doctor's prescription.
The company is studying hibernating animals to see if their genomes contain novel biological pathways that could be exploited to counteract complex human diseases.
News items for the week of March 1, 2021.
The company also said that a previously granted EUA for its Alinity m SARS-CoV-2 assay has been expanded to include asymptomatic individuals and pooled testing.
R-Pharm, Illumina's strategic partner in Russia and the Commonwealth of Independent States (CIS), led the registration process with the Russian regulatory agency.
For the three months ended Dec. 31, 2020, the La Jolla, California-based firm posted $2.1 million in revenues, up from $1.6 million in Q4 2019.
The firm plans to use $561 million of the net proceeds to fund the majority of its planned $591 million acquisition of Oxford Immunotec.
The Temple City, California-based firm delivered approximately 3.2 million billable tests in the quarter and recorded $295.0 million in revenues.
The company said that it sold 57 T2Dx instruments in 2020, including 47 in the US, more than doubling its US installed base.
Barrow Neurological Institute and the University of Utah will use Datavant technology to link known mutations to phenotypes in the disease registry.
With genetic data from nearly 18,500 Finnish individuals, investigators retraced fine-scale population patterns in the country over several decades.
Two studies identified common and rare regulatory variants in iPSC lines, including those with ties to disease or differentiation.
C2i said that the acquisition would help it commercialize its MRDetect cancer monitoring platform as a reimbursable laboratory-developed test.
The test is designed to assess the risk of a person developing severe disease if they contract COVID-19 based on a combination of genetic and clinical factors.
The company sold two series of senior notes totaling $500 million that it said it plans to use to repay outstanding debt and for general corporate purposes.
The firm said that with the addition of a target for SARS-CoV-2, its high-throughput NxTag syndromic respiratory panel includes 19 viral and two bacterial targets.
The firm plans to use the proceeds to fund the redemption of senior notes due in 2022 and for general corporate purposes.
Bio-Techne said Asuragen's headquarters in Austin, Texas includes a scalable 50,000-square-foot manufacturing facility and CLIA-certified laboratory.
Following completion of the offering of American Depositary Shares, the company will list on the Nasdaq Global Market under the symbol OLK.
QiaCube Connect MDx is designed specifically for IVD applications, and automates DNA, RNA, and protein sample processing using Qiagen spin column technology.
Tempus will assist Texas Oncology subsidiary Precision Health Informatics in mining its database for precision oncology insights to inform research.
Otsuka said it will use the CRISPR-Cas9 technology to support its internal research and development programs.
At AGBT, UCSC's Karen Miga provided updates on the human pangenome reference project and the telomere-to-telomere consortium's genome assembly work.
In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.
National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.
Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.
In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.